IDiyas

For the Inventor, By the Inventor

Richmond, CA, United States of America

Surjit Bhimarao Dixit

USPTO Granted Patents = 27

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 254(Granted Patents)


Location History:

  • Richmond, CA (US) (2016)
  • Richmond, CA (2016 - 2022)

Company Filing History:

goldMedal27 out of 56 
 
Zymeworks Inc.
 patents

Years Active: 2016-2022

Loading Chart...
27 patents (USPTO):Explore Patents
1. 11325981 - Bispecific antigen-binding constructs targeting Her2 (2022-05-10),
2. 11306156 - Modified antigen binding polypeptide constructs and uses thereof (2022-04-19),
3. 11286293 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2022-03-29),
4. 11248037 - Multivalent heteromultimer scaffold design and constructs (2022-02-15),
5. 11152081 - Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics (2021-10-19),
6. 11078296 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2021-08-03),
7. 11031093 - Systems and methods for identifying thermodynamically relevant polymer conformations (2021-06-08),
8. 10947319 - Bispecific antigen-binding constructs targeting HER2 (2021-03-16),
9. 10875931 - Stable heterodimeric antibody design with mutations in the Fc domain (2020-12-29),
10. 10711051 - Multivalent heteromultimer scaffold design and constructs (2020-07-14),
11. 10508154 - Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells (2019-12-17),
12. 10482991 - Systems and methods for sampling and analysis of polymer conformational dynamics (2019-11-19),
13. 10457742 - Stable heterodimeric antibody design with mutations in the Fc domain (2019-10-29),
14. 10358479 - Multivalent heteromultimer scaffold design and constructs (2019-07-23),
15. 10155803 - Multivalent heteromultimer scaffold design and constructs (2018-12-18),

Title: Surjit Bhimarao Dixit: Pioneering Innovations in Cancer Treatment

Introduction:

Surjit Bhimarao Dixit, based in Richmond, CA (US), is a remarkable inventor who has made significant contributions to the field of cancer treatment. With an impressive portfolio of 27 patents, Dixit has consistently pushed the boundaries of scientific research and innovation. This article aims to shed light on his latest inventions, working company, and noteworthy collaborations.

Latest Inventions:

Dixit's latest patents include groundbreaking technology that focuses on bispecific antigen-binding constructs targeting HER2. These constructs involve two antigen-binding moieties; one binds to ECD2 of HER2, while the other binds to ECD4 of HER2. These biparatopic antigen-binding constructs, which often involve a single-chain variable fragment (scFv), show immense potential in cancer treatment. They can be effectively utilized for targeted therapy, further advancing treatment options for individuals diagnosed with HER2-overexpressing cancers.

Furthermore, Dixit's inventive work also encompasses modified antigen-binding polypeptide constructs. These constructs employ heterodimer pairs, comprising modified immunoglobulin heavy chains and light chains. The modifications within the CH1 and/or CL domains as well as the VH and/or VL domains create preferential pairing between the heavy and light chains. This optimization allows for improved functionality and selectivity within the heterodimer pair, thus enhancing their therapeutic potential.

Zymeworks Inc.:

Surjit Bhimarao Dixit is an invaluable asset to Zymeworks Inc., a renowned biotechnology company specializing in the development of multifunctional biotherapeutics. Zymeworks aims to improve the lives of patients by leveraging innovative antibody and protein engineering technologies. With Dixit's expertise and contribution to the company, Zymeworks continues to make significant strides in the field of cancer therapeutics.

Collaborators:

Surjit Bhimarao Dixit has had the privilege of working alongside visionary individuals in his groundbreaking research. Noteworthy collaborators include Thomas Spreter Von Kreudenstein and Paula Irene Lario. Their collective efforts have paved the way for revolutionary advancements in the development of novel cancer treatments.

Conclusion:

Surjit Bhimarao Dixit's remarkable portfolio of 27 patents speaks volumes about his dedication and expertise in the field of cancer therapeutics. His inventions, including the bispecific antigen-binding constructs and modified antigen-binding polypeptide constructs, have opened new avenues in targeted cancer treatment. By partnering with Zymeworks Inc., Dixit continues to contribute to the advancement of scientific innovation, potentially leading to improved patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…